Latest Headlines

  1. Pelago Bioscience Acquires RG Discovery, Forming An Integrated Drug Discovery Partner Spanning Biology And Chemistry 6/15/2026

    Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery.

  2. TuHURA Biosciences Files Investigational New Drug Application For Evaluation Of The TBS-2025 VISTA Inhibiting Antibody In Molecularly Defined Subsets Of AML And Other Blood Related Cancers 6/15/2026

    TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the study of its TBS-2025 VISTA inhibiting antibody for the treatment of molecularly defined subsets of AML and other blood related cancers.

  3. Porosome Therapeutics Announces Global Drug Development Partnership With The Largest Governmental R&D Organization In India 6/15/2026

    Porosome Therapeutics, Inc., announced today that it has entered into a drug development partnership with the Council of Scientific and Industrial Research (CSIR) of the Government of India, the premier scientific research and development organization in the country.

  4. Harbour BioMed Announces NMPA Acceptance Of IND Application For HBM7004 For The Treatment Of Advanced Solid Tumors 6/10/2026

    Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the National Medical Products Administration (NMPA) of China has accepted the Investigational New Drug (IND) application for HBM7004 for the treatment of advanced solid tumors.

  5. Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical And AI Companies To Accelerate AI-enabled Drug Discovery 6/10/2026

    Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery.

  6. XtalPi Announces Strategic Partnership With A Leading Biopharma To Develop Oral Small Molecule Therapeutics For A GPCR Target 6/10/2026
  7. US FDA Grants Orphan Drug And Rare Pediatric Disease Designations To GEn1E Lifesciences' Dual Signal Modulator For The Treatment Of Duchenne Muscular Dystrophy 6/10/2026

    GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven precision medicines for immunology, inflammation, and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to GEn-1123 for the treatment of Duchenne Muscular Dystrophy (DMD).

  8. Ignite Biomedical And Liquid Biosciences Partner To Discover First-In-Class Drug Targets 6/9/2026

    Ignite Biomedical, Inc. ("Ignite") and Liquid Biosciences, developer of the Emerge AI platform, today expanded their collaboration into drug-target discovery for new therapeutic development.

  9. Perpetual Medicines And Third Rock Ventures Deliver A Development Candidate In Under 18 Months Via Computational Physics And AI-Driven Platform 6/9/2026

    Perpetual Medicines, a biotechnology company pioneering the integration of computational physics and artificial intelligence for complex drug discovery, today announced the successful delivery of a development candidate in collaboration with Third Rock Ventures.

  10. OpenFold Consortium Adds Eleven New Members As Momentum Builds For Open AI Infrastructure In Biology And Drug Discovery 6/9/2026

    OpenFold Consortium, an open science initiative advancing open-source AI tools for biology and drug discovery, announced today that eleven new members have joined the consortium including Absci, Adaptive Biotechnologies, Benchling, Chemical Computing Group, Daiichi Sankyo, Flagship Pioneering, Kiin Bio, Nanome, Nxera, Pledge Tx, and Superluminal.